ASP Isotopes Files 8-K for Regulation FD Disclosure
Ticker: ASPI · Form: 8-K · Filed: Sep 15, 2025 · CIK: 1921865
Sentiment: neutral
Topics: regulation-fd, disclosure
TL;DR
ASP Isotopes filed an 8-K for a Reg FD disclosure, no new material info disclosed.
AI Summary
ASP Isotopes Inc. filed an 8-K on September 15, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.
Why It Matters
This filing indicates ASP Isotopes Inc. is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not report any new material events, financial changes, or significant business developments.
Key Players & Entities
- ASP Isotopes Inc. (company) — Registrant
- September 15, 2025 (date) — Date of Report
- Regulation FD (regulation) — Disclosure type
- Delaware (jurisdiction) — State of Incorporation
- 202-756-2245 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the exact name of the registrant?
The exact name of the registrant is ASP Isotopes Inc.
On what date was this report filed?
The report was filed on September 15, 2025.
In which state was ASP Isotopes Inc. incorporated?
ASP Isotopes Inc. was incorporated in Delaware.
What is the principal executive office address of ASP Isotopes Inc.?
The principal executive office address is 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004.
Filing Stats: 885 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-15 12:14:25
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 ASPI The Nasdaq Stock Market LLC
Filing Documents
- aspi_8k.htm (8-K) — 28KB
- 0001477932-25-006736.txt ( ) — 147KB
- aspi-20250915.xsd (EX-101.SCH) — 5KB
- aspi-20250915_lab.xml (EX-101.LAB) — 15KB
- aspi-20250915_cal.xml (EX-101.CAL) — 1KB
- aspi-20250915_pre.xml (EX-101.PRE) — 10KB
- aspi-20250915_def.xml (EX-101.DEF) — 2KB
- aspi_8k_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 15, 2025, ASP Isotopes Inc. (the "Company" or "ASP Isotopes") extended the date for the fulfillment of the conditions to the previously announced offer by the Company to acquire 100% of the ordinary shares (excluding treasury shares) of Renergen Limited ("Renergen"), a South African company listed on the exchange operated by the JSE Limited and the Australian Securities Exchange, pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the "Scheme"). The Company has extended the longstop date from September 30, 2025 to November 28, 2025 in order to allow the parties additional time to satisfy conditions to closing relating to the receipt of the remaining required regulatory approval and certain third party consents. As of September 15, 2025, the implementation of the Scheme remained subject to the approval of the Financial Surveillance Department of the South African Reserve Bank (FinSurv) as provided for in the South African Exchange Control Regulations (in terms of the South African Currency and Exchanges Act, 1933). The Company and Renergen continue to pursue a timely approval of the Scheme with FinSurv and certain third parties in order to implement the Scheme as promptly as possible.
Forward Looking Statements
Forward Looking Statements This Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "estimate," "project," "continue," and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all; (ii) the satisfaction of the Scheme conditions; (iii) the failure to obtain necessary regulatory approvals; (iv) the ability to realize the anticipated benefits of the proposed acquisition of Renergen; (v) the ability to successfully integrate the businesses; (vi) disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; (vii) the negative effects of this announcement or the consummation of the proposed acquisition of Renergen on the market price of Renergen's or ASPI's securities; (viii) significant transaction costs and unknown liabilities; (ix) litigation or regulatory actions related to the proposed acquisition of Renergen; and (x) such other factors as are set forth in the periodic reports filed by ASPI with the U.S. Securities and Exchange Commission (the "SEC"), including but not limited to those described under the heading "Risk Factors" in its annual reports on Form 10-K, quarterly reports on Form 10-Q and any other filings made with the SEC from time to time, which are available via the SEC's website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipa
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASP ISOTOPES INC. Date: September 15, 2025 By: /s/ Donald G. Ainscow Name: Donald G. Ainscow Title: Executive Vice President, General Counsel and Secretary 3